title: Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
abstract: OBJECTIVE
  ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation.
  
  
  METHODS
  ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121).
  
  
  RESULTS
  High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028).
  
  
  CONCLUSIONS
  This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.
authors.affiliation: Oncology Department, x2018;S. Giovanni Calibita' Fatebenefratelli Isola Tiberina Hospital, Rome, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Ciaparrone
authors.forename: Orietta
authors.initials: O
authors.lastname: Caspiani
authors.forename: Giulio
authors.initials: G
authors.lastname: Bicciolo
authors.forename: Diego
authors.initials: D
authors.lastname: Signorelli
authors.forename: Ilaria
authors.initials: I
authors.lastname: Simonelli
authors.forename: Luca
authors.initials: L
authors.lastname: de Campora
authors.forename: Giorgio
authors.initials: G
authors.lastname: Mazzarella
authors.forename: Antonella
authors.initials: A
authors.lastname: Mecozzi
authors.forename: Curzio
authors.initials: C
authors.lastname: Pianelli
authors.forename: Angelo
authors.initials: A
authors.lastname: Camaioni
authors.forename: Piera
authors.initials: P
authors.lastname: Catalano
authors.forename: Patrizio
authors.initials: P
authors.lastname: Pasqualetti
authors.forename: Alfredo
authors.initials: A
authors.lastname: Fabiano
authors.forename: Marco
authors.initials: M
authors.lastname: Radici
authors.forename: Luca
authors.initials: L
authors.lastname: Marmiroli
authors.forename: Domenico Cristiano
authors.initials: DC
authors.lastname: Corsi
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D059186:Chemoradiotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin